Akums drugs & pharma has announced its quarterly earnings conference call to discuss the unaudited financial results for Q3FY26. The pharmaceutical company filed the requisite disclosure with stock exchanges on January 31, 2026, in compliance with regulation 30 of SEBI listing requirements.

Earnings Call Schedule

The earnings call is scheduled for February 16, 2026, at 12:00 PM IST. The conference will be hosted in collaboration with Ambit Capital, with Gaurav Tinani from Institutional Equities serving as the moderator for the session.

Company Representatives

The earnings call will feature senior leadership from Akums Drugs & Pharmaceuticals Limited to discuss the quarterly performance and address analyst queries:

• Mr. Sanjeev Jain - Managing Director
• Mr. Sandeep Jain - Managing Director
• Mr. Sumeet Sood - Chief Financial Officer
• Mr. Sahil Maheshwari - Head Strategy

Conference Access Details

The company has provided multiple access options for participants to join the earnings call. Domestic participants can use the primary access numbers, while international participants have dedicated toll-free numbers for various regions.

Regulatory Compliance

The earnings call announcement was made pursuant to regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Dharamvir Malik signed the disclosure document, which has been updated on the company's website at www.akums.in for stakeholder reference.

Akums drugs & pharma has secured European GMP certificates for its two manufacturing facilities located at Haridwar, Uttarakhand, marking a significant regulatory milestone for the pharmaceutical company. The certification was granted by the Bulgarian Drug Agency (BDA) and represents both a renewal and a fresh approval for the company's manufacturing capabilities.

Certification Details

The European GMP certificates cover two distinct facilities with different approval statuses:

Both certifications are valid for a period of three years, extending until October 2028, providing the company with a stable regulatory framework for European market operations.

Market Access and Business Impact

The European GMP accreditations will enable Akums Drugs and Pharmaceuticals Limited to expand its market reach significantly. The certifications provide access to:

• EU regulated markets
• Several other international markets that follow EU-GMP regulations
• New business opportunities from European Union countries

The company has already positioned itself to leverage these approvals, with Plant 2 designated to service the European CDMO contract that was signed in December 2024.

Manufacturing Capabilities

With the new certifications, each facility is authorized for specific product categories:

Plant 1 Authorization:

• Tablets manufacturing and supply
• Hard gelatine capsules production
• Sachet dosage forms

Plant 2 Authorization:

• Oral liquid formulations manufacturing
• Supply capabilities for EU countries
• Service delivery for European CDMO operations

Regulatory Compliance

The company disclosed this development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating its commitment to transparency and regulatory compliance. The Bulgarian Drug Agency serves as the regulatory authority for these European GMP certifications, ensuring adherence to stringent European pharmaceutical manufacturing standards.

These certifications represent a strategic advancement for Akums Drugs and Pharmaceuticals Limited, positioning the company to capitalize on European market opportunities while maintaining compliance with international pharmaceutical manufacturing regulations.